# AbbVie Raises Full-Year Guidance as Non-GAAP EPS Beats Estimates

By John Kim

Canonical URL: https://www.tokenpost.com/news/business/44682
Published: 2026-10-30T12:46:56.000Z
Updated: 2026-10-30T12:46:56.000Z
Section: Business

> Third-quarter revenue reached $17.4 billion, up 10.3% year over year, while the immunology portfolio generated $9.165 billion in global net revenue.

AbbVie raised its full-year guidance after third-quarter revenue and non-GAAP earnings per share beat estimates, with its immunology portfolio also posting higher global net revenue.

Revenue totaled $17.4 billion, up 10.3% from a year earlier and $50 million above estimates. Non-GAAP earnings per share was $3.82, exceeding estimates by $0.05.

The immunology portfolio generated $9.165 billion in global net revenue during the quarter, a 16.3% increase on a reported basis.